menu
    • menu
    [{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Catalys Pacific","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Catalys Pacific"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Renalys Pharma \/ Renalys Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Renalys Pharma"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.20000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Chugai Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Renalys Pharma

    Menu

    Renalys Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : $203.8 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chugai Pharmaceutical to Acquire Renalys Pharma

                            Details : Under the acquisition of Sparsentan, the deal aims to advance treatment for IgA nephropathy by targeting Endothelin receptor ET-A and Type-1 angiotensin II receptor.

                            Product Name : Filspari

                            Product Type : Miscellaneous

                            Upfront Cash : $98.6 million

                            October 24, 2025

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : $203.8 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sparsentan Phase 3 Enrollment Completed for IgA Nephropathy in Japan

                            Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sparsentan Receives Orphan Drug Designation for Primary IgA Nephropathy in Japan

                            Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renalys Pharma Doses First Patient in Phase III Trial of Sparsentan for IgA Nephropathy

                            Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Catalys Pacific

                            Deal Size : $38.8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Renalys Pharma Closes ¥60Bn Financing to Advance Kidney Disease Treatments in Asia

                            Details : The financing will enable Renalys Pharma to complete its Phase III clinical trial for RE-021 (sparsentan), a promising treatment for IgA nephropathy, in Japan.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 17, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Catalys Pacific

                            Deal Size : $38.8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renalys Submits IND Application for Sparsentan Phase III Trial in Japan

                            Details : Filspari (sparsentan) is a once-daily oral medication targeting critical pathways in IgAN, approved for the treatment of IgA nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renalys Pharma Launches Innovative Medicines in Japan and Asia

                            Details : Filspari (sparsentan) is an oral medication targeting key pathways in IgAN disease progression, approved for treating IgA nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Recipient : Travere Therapeutics

                            Deal Size : $120.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Travere Announces Agreement with Renalys for Sparsentan in Japan and Southeast Asia

                            Details : Under the agreement, Renalys will bring Filspari (sparsentan), a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.

                            Product Name : Filspari

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Recipient : Travere Therapeutics

                            Deal Size : $120.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth